Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib Combined With Chemotherapy in Advanced NSCLC
NCT06328049Phase 2Recruiting
- Sponsor
- Taixing People's Hospital
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib in febrile neutropenia (FN), sponsored by Taixing People's Hospital. Primary endpoint: Incidence of febrile neutropenia (FN) at 21 days. Started Aug 2023; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT06328049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328049.